Siminoff LA, Fetting JHEffects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. Med Decis Making1989; 9: 262-71.
2.
Featherstone K., Donovan JL`Why don't they just tell me straight, why allocate it?` The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med2002; 55: 709-19.
3.
Flory J., Emanuel E.Interventions to improve research participants' understanding in informed consent for research. JAMA2004; 292(13): 1593-601.
4.
Wadey V., Frank C.The effectiveness of patient verbalization on informed consent. Can J Surg1997; 40(2): 124-28.
5.
Kass N., Sugarman J., Taylor H., Fogarty L., Goodman SN, Goodwin-Landher A., et al. Purpose and benefits of early phase cancer trials: What do oncologists say? What do patients hear?JERHRE2008 September 2008:57-68.
6.
von Hoff DD, Turner J.Response rates, duration of response, and dose response effect in Phase I studies in antineoplastics. Invest New Drugs1997; 9: 115-22.
7.
Arkenau H., Olmos D., Ang JE et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience . Br J Cancer2008; 98: 1029-33.
8.
Horstmann E. , McCabe M., Grochow L. et al. Risks and benefits of phase I oncology trials, 1991 through 2002. NEJM2005; 352(9): 895-904.
